Lexaria Bioscience Corp LEXX

Alternate Symbol(s): LEXXW

Healthcare

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

NDAQ:LEXX - Post by User

Lexaria Bioscience Corp

<< Previous

Bullboard Posts

Next >>

Post by JasleenDhakaon Mar 01, 2023 2:35pm

144 Views

Post# 35313163

Lexaria discovers potential novel mechanism..

Lexaria Bioscience Corp.: Discovers potential novel mechanism from hypertension study

Our analyst opinion: Studies indicated that Lexaria’s DehydraTECH™-enabled CBD has potential to reduce catestatin (a contributor of hypertension). This is a positive development as Lexaria is planning phase 1(b) tests this year.

Read our Weekly Industry Insights for more: https://www.researchfrc.com/our-near-term-outlook-for-the-us-and-metal-prices/

*FRC provides issuer-paid coverage.
*Past performance is not indicative of future results.

<< Previous

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition